Teladoc, Inc. (NYSE:TDOC) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, July 25th.
Several other brokerages have also weighed in on TDOC. Cantor Fitzgerald lowered shares of Teladoc from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $23.00 to $27.00 in a research report on Thursday, April 6th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Piper Jaffray Companies upped their price target on shares of Teladoc from $26.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 11th. TheStreet lowered shares of Teladoc from a “c-” rating to a “d” rating in a report on Monday, July 3rd. Finally, Craig Hallum downgraded shares of Teladoc from a “buy” rating to a “hold” rating and increased their price objective for the company from $28.00 to $32.00 in a research note on Friday, May 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $33.77.
Shares of Teladoc (NYSE:TDOC) traded up 2.15% during trading on Tuesday, hitting $30.90. The stock had a trading volume of 1,348,105 shares. The stock has a 50 day moving average of $34.47 and a 200 day moving average of $26.96. Teladoc has a 12 month low of $13.49 and a 12 month high of $36.90. The company’s market cap is $1.69 billion.
Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. Teladoc had a negative return on equity of 22.20% and a negative net margin of 47.75%. The firm had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same quarter last year, the firm earned ($0.38) earnings per share. The company’s revenue was up 68.3% compared to the same quarter last year. Equities analysts forecast that Teladoc will post ($1.27) EPS for the current fiscal year.
In related news, CEO Jason N. Gorevic sold 15,000 shares of the stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $23.11, for a total transaction of $346,650.00. Following the completion of the sale, the chief executive officer now directly owns 833,261 shares of the company’s stock, valued at approximately $19,256,661.71. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jason N. Gorevic sold 5,600 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $29.57, for a total value of $165,592.00. Following the sale, the chief executive officer now directly owns 823,861 shares of the company’s stock, valued at $24,361,569.77. The disclosure for this sale can be found here. Insiders have sold a total of 168,380 shares of company stock valued at $4,805,918 over the last three months. Company insiders own 5.94% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp increased its position in Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock worth $6,309,000 after buying an additional 9,146 shares during the period. Teachers Advisors LLC increased its position in Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock worth $581,000 after buying an additional 1,759 shares during the period. Peregrine Capital Management LLC increased its position in Teladoc by 24.1% in the first quarter. Peregrine Capital Management LLC now owns 903,384 shares of the health services provider’s stock worth $22,539,000 after buying an additional 175,158 shares during the period. First Mercantile Trust Co. purchased a new position in Teladoc during the first quarter worth $175,000. Finally, Russell Investments Group Ltd. purchased a new position in Teladoc during the first quarter worth $583,000. 94.48% of the stock is owned by hedge funds and other institutional investors.
About Teladoc
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
